BETA: Please send your feedback!

Intercept Pharmaceuticals

ICPT:NAS

Pharmaceuticals: Other

$0
SMALL cap
$58.40 (-4.56%)
-0.59%
since start of 2020
-5.36
  • 2
  • 2
  • 1
  • —
  • —
  • 2
  • 5
  • 1
  • —
  • —
  • —
  • 3
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

About

Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
 website

Headquarters

37th floor
10 Hudson Yards
New York, NY 10001
1.646.747.1000

Executives

Name Title Gender
David A. Shapiro, MD Chief Medical Officer & Executive VP-Development Male
Mark E. Pruzanski, MD President, Chief Executive Officer & Director Male
Paolo Fundar˜ Chairman Male
Roberto Pellicciari, PhD Founder Male
Mark J. Vignola, PhD Director-Investor Relations Male
Sandip S. Kapadia, MBA, CPA Chief Financial Officer Male
Jerome B. Durso Chief Operating Officer Male

Mindful Investing Summary

  • —
  • 1
  • 2
  • 3
  • 4
  • 5
  • Carbon Footprint
    — N/A
  • Pollution Prevention
    — N/A
  • Water Conservation
    — N/A
  • Data & Privacy Protection
    — N/A
  • Consumer Health, Wellness & Safety
    — N/A
  • Employee Ownership, Satisfaction, Benefits & Pay
    — N/A
  • Workplace Health and Safety
    — N/A
  • Integrity of Corporate Governance
    — N/A
  • Ethical Practices
    — N/A
  • Usage of Conflict Materials
    — N/A
  • Forced Labor
    — N/A
  • Diversity of Corporate Leadership
    1 N/A

Intercept Pharmaceuticals - Competitors and Related Companies

How Intercept Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.

Intercept Pharmaceuticals

ICPT:NAS

Pharmaceuticals: Other

$0
SMALL cap
$58.40 (-4.56%)
-0.59%
since start of 2020
-5.36
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

MediciNova

MNOV:NAS

Biotechnology

$152.09mm
SMALL cap
$3.46 (-0.26%)
-0.56%
since start of 2020
-11.50
  • 2
  • 2
  • 1
  • —
  • —
  • 2
  • 5
  • 1
  • —
  • —
  • —
  • 3
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Conatus Pharmaceuticals

CNAT:NAS

Biotechnology

$10.08mm
MICRO cap
$0.30 (-0.01%)
-0.26%
since start of 2020
-0.89
  • 2
  • 2
  • 1
  • —
  • —
  • 2
  • 5
  • 1
  • —
  • —
  • —
  • 3
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Bristol-Myers Squibb

BMY:NYS

Pharmaceuticals: Major

$124.03bn
MEGA cap
$54.82 (-0.92%)
-0.16%
since start of 2020
24.91
  • 2
  • 5
  • 4
  • 3
  • —
  • 4
  • 5
  • 1
  • 5
  • —
  • —
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Eli Lilly

LLY:NYS

Pharmaceuticals: Major

$130.56bn
MEGA cap
$136.42 (-2.30%)
0.02%
since start of 2020
27.18
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • 3
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Gilead Sciences

GILD:NAS

Biotechnology

$91.29bn
MEGA cap
$72.51 (-2.25%)
0.08%
since start of 2020
17.11
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5